EDG-7 siRNA (h) from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

EDG-7 siRNA (h)

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
EDG-7 siRNA (h)

Description

EDG-7 siRNA (h)

Product Specs
ItemEDG-7 siRNA (h)
CompanySanta Cruz Biotechnology, Inc.
Price $293.00Supplier Page View Company Product Page
Catalog Numbersc-37088
Gene Namelysophosphatidic acid receptor 3
Quantity10 µM
Specieshuman
NCBI Full Gene Namelysophosphatidic acid receptor 3
NCBI Gene AliasesEDG7, Edg-7, GPCR, HOFNH30, LP-A3, LPA3, RP4-678I3
TypesiRNA/dsRNA

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) LPA_1/3 signaling mediates tumor lymphangiogenesis through promoting CRT expression in prostate cancerBiochimica et biophysica acta. Molecular and cell biology of lipidsOctober 1, 2018Lin YC, Chen CC, Chen WM, Lu KY, Shen TL, Jou YC, Shen CH, Ohbayashi N, Kanaho Y, Huang YL, et al.

(2) Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cellsOncotargetJanuary 19, 2016Zuckerman V, Sokolov E, Swet JH, Ahrens WA, Showlater V, Iannitti DA, Mckillop IH.

(3) Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancersClinical and experimental medicineAugust 1, 2015Sun K, Cai H, Duan X, Yang Y, Li M, Qu J, Zhang X, Wang J.

(4) Lysophosphatidic acid induces reactive oxygen species generation by activating protein kinase C in PC-3 human prostate cancer cellsBiochemical and biophysical research communicationsNovember 1, 2013Lin CC, Lin CE, Lin YC, Ju TK, Huang YL, Lee MS, Chen JH, Lee H.

(5) Lysophosphatidic acid receptor 2/3-mediated IL-8-dependent angiogenesis in cervical cancer cellsInternational journal of cancerAugust 15, 2012Chen RJ, Chen SU, Chou CH, Lin MC.

(6) Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancerFASEB journal : official publication of the Federation of American Societies for Experimental BiologyAugust 1, 2012Cai Q, Zhao Z, Antalis C, Yan L, Del Priore G, Hamed AH, Stehman FB, Schilder JM, Xu Y.

(7) Lysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cellsPloS oneJanuary 1, 2012Lin CE, Chen SU, Lin CC, Chang CH, Lin YC, Tai YL, Shen TL, Lee H.

(8) Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation- and EGFR transactivation-dependent mechanismsCellular signallingOctober 1, 2008Lin CI, Chen CN, Huang MT, Lee SJ, Lin CH, Chang CC, Lee H.

(9) Lysophosphatidic acid up-regulates expression of interleukin-8 and -6 in granulosa-lutein cells through its receptors and nuclear factor-kappaB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndromeThe Journal of clinical endocrinology and metabolismMarch 1, 2008Chen SU, Chou CH, Lee H, Ho CH, Lin CW, Yang YS.

Be the First to Write a Review!